We are live on ! Find out more
BIAFW icon

bioAffinity Technologies
BIAFW

5 hedge funds and large institutions have $26.3K invested in bioAffinity Technologies in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.03% more ownership

Funds ownership: 3.34% → 3.37% (+0.03%)

0% more funds holding

Funds holding: 5 → 5 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

81% less capital invested

Capital invested by funds: $137K → $26.3K (-$111K)

Holders
5
Holders Change
–
Holders Change %
0%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$3.14K
2
CS
Clear Street
New York
+$30

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$842
2
WAM
Warberg Asset Management
Illinois
-$507
3
UBS Group
UBS Group
Switzerland
-$60

BIAFW Hedge Fund Activity: Q3 2023 in Review

5 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in bioAffinity Technologies (BIAFW) for Q3 2023, worth a combined $26.3K — down 81% from $137K a quarter earlier.

Fund positioning in BIAFW was balanced in Q3 2023: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 2 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $3.14K. The largest seller was Citadel Advisors, cutting an estimated $842.

  • 5 institutional investors held bioAffinity Technologies (BIAFW) as of Q3 2023, unchanged from Q2 2023.
  • Funds reported $26.3K of bioAffinity Technologies stock for Q3 2023, down 81% quarter-over-quarter.
  • 1 fund opened new bioAffinity Technologies positions in Q3 2023 and 1 closed out, a net change of 0 holders.
  • The largest bioAffinity Technologies buyer in Q3 2023 was Susquehanna International Group, an estimated $3.14K added.
  • The largest bioAffinity Technologies seller in Q3 2023 was Citadel Advisors, an estimated $842 sold.

Based on aggregated 13F filings for Q3 2023.